Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda

Lisa Nkatha Micheni1,2, Kennedy Kassaza1, Hellen Kinyi3, Ibrahim Ntulume2, Joel Bazira1,*

1 Department of Microbiology, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda, 2 Department of Microbiology and Immunology, Faculty of Biomedical Sciences, Kampala International University Western Campus, Bushenyi, Uganda, 3 Department of Biochemistry, School of Medicine, Kabale University, Kabale, Uganda

* jbazira@must.ac.ug

Abstract

Multidrug-resistant tuberculosis (MDR-TB) has become a major threat to the control of tuberculosis globally. Uganda is among the countries with a relatively high prevalence of tuberculosis despite significant control efforts. In this study, the drug resistance of Mycobacterium tuberculosis to rifampicin (RIF) and isoniazid (INH) was investigated among patients diagnosed with pulmonary tuberculosis in Southwestern Uganda. A total of 283 sputum samples (266 from newly diagnosed and 17 from previously treated patients), collected between May 2018 and April 2019 at four different TB diagnostic centres, were assessed for RIF and INH resistance using high-resolution melt curve analysis. The overall prevalence of monoresistance to INH and RIF was 8.5% and 11% respectively, while the prevalence of MDR-TB was 6.7%. Bivariate analysis showed that patients aged 25 to 44 years were at a higher risk of developing MDR-TB (cOR 0.253). Furthermore, among the newly diagnosed patients, the prevalence of monoresistance to INH, RIF and MDR-TB was 8.6%, 10.2% and 6.4% respectively; while among the previously treated cases, these prevalence rates were 5.9%, 23.5% and 11.8%. These rates are higher than those reported previously indicating a rise in MTB drug resistance and may call for measures used to prevent a further rise in drug resistance. There is also a need to conduct frequent drug resistance surveys, to monitor and curtail the development and spread of drug-resistant TB.

Introduction

Tuberculosis (TB) is a severe infectious disease associated with high rates of mortality and morbidity worldwide despite intense efforts. One of the major factors sustaining the TB epidemic is the increasing number of Mycobacterium tuberculosis (MTB) strains that do not respond to TB therapy [1–4]. Currently, the standard TB treatment regimen combines four first-line antibiotics, isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), which renders a patient noncontagious when they are properly administered.
However, inadequate treatment can result in drug-resistant MTB among these patients (acquired resistance), and those resistant strains can be transmitted to other individuals (primary resistance). MDR-TB, described as resistance to both INH and RIF (the two most effective antibiotics for TB treatment) is of great concern because second-line antimycobacterial drugs require long-term administration, are expensive, and have a wide variety of side effects [5]. MDR-TB emerged in the early 1990s and continues to rise each year [1, 6]. In 2017 the world health organization (WHO) reported that approximately 4.1% of new TB cases and 19% of previously treated cases had developed multidrug resistance [7]. In Uganda, the prevalence of MDR-TB is estimated at 12% and 1% among previously-treated and newly diagnosed patients respectively by 2019 [8]. Continuous screening of antibiotic resistance in TB patients, focusing primarily on INH and RIF, is critical since these two medications are the backbone of TB treatment [9]. Resistance to RIF is related to mutations in the rpoB gene, which encodes the β-subunit of bacterial DNA-dependent RNA polymerase, while INH resistance is a result of two pathways involving large mutations in the katG (encodes a catalase-peroxidase enzyme which converts INH to its active form) and inhA genes [10]. An amino acid substitution on codon 315 of katG due to mutation accounts for 42%–95% of INH resistance [11] while a mutation at the promoter region of the inhA gene encoding the enoyl-ACP-reductase, confers 6%–34% of INH resistance in MTB strains [11]. There are several techniques applied in the detection of drug resistance. The conventional drug susceptibility testing (DST) systems which focus on the culture of MTB is time-consuming as it takes approximately 2 to 4 weeks due to the slow growth of this bacteria [12]. Other approaches such as microscopic observation drug susceptibility (MODS; Hardy Diagnostics) and thin-layer agar (TLA; NanoLogix, Inc.) assays are quicker but are highly operator dependent, expensive and technically challenging in resource-limited areas [12]. The establishment of Molecular techniques that identify mutations associated with drug resistance drastically decreases the diagnostic delay and, in some cases, may prove to be more specific than phenotypic DST [13]. High-resolution melt curve analysis (HRMA) is a molecular technique that can be used to detect subtle genetic mutations conferring drug resistance in MTB and is based on the detection of a variation of the deoxyribonucleic acid (DNA) sequence demonstrated by fluorescence changes in the melting temperature of a double-stranded DNA amplicon after real-time polymerase chain reaction (qPCR) [14]. This overall sensitivity and specificity of HRMA is approximately 94% and 99%, respectively in the detection of MDR-TB [15–17]. It is also simple, quick and easy to perform hence can be used to screen a vast number of samples within a limited time. This study utilized the HRMA technique to screen for RIF and INH among patients diagnosed with pulmonary tuberculosis (PTB) in Southwestern Uganda, a region heavily affected by the TB/HIV epidemic [18, 19].

Materials and methods

Ethics approval and consent to participate

Ethical clearance for this study was obtained from the Mbarara University of Science and Technology Institutional Review Board committee (ref. 13/08-17) and clearance was acquired from the Uganda National Council for Science and Technology Research under (ref. HS2379). Permission was also obtained from the office of the Prime minister to access the refugee camps while the health facility administrators granted permission to access their facilities. Participants consented to enroll in the study upon completing an informed consent form.

Study setting and population

This was a cross-sectional study conducted in the Southwestern region of Uganda between May 2018 and April 2019. The Cochran sampling technique [20] was used to determine the
sample size and a total of 283 consenting patients were recruited. Four recruitment centres were utilized; two regional referral hospitals (Kabale and Mbarara regional referral hospitals) and two health centres located within two refugee camps (Oruchinga and Nakivale health centre IV). Patients aged $\geq$ 18 years, diagnosed with PTB for the first time and those previously treated for TB at any of the four study locations were eligible to participate in this study. Non-sputum samples from patients with extrapulmonary TB were excluded.

Data and sample collection

Sputum samples from eligible patients were collected and confirmed for TB using either smear microscopy or Cepheid GeneXpert. Besides the sample collection, demographic characteristics such as age, gender, ethnicity, place of residence, level of income, HIV status before enrollment were obtained from the eligible patients using a standard clinical form. Information about certain risk factors for exposure to resistant strains including imprisonment, previous history of TB treatment and history of recent migration into the country were also collected. The sputum samples were refrigerated at 4°C at the recruitment centres, for not more than 72 hours, and later transported in a cold box to Mbarara University of Science and Technology Genomics and Translational Laboratory for processing and molecular analysis.

DNA extraction and confirmation of MTB in sputum samples

The genomic DNA from each patients’ sputum sample was processed by standardized protocols [21, 22]. The samples were then screened and confirmed as MTB by detection of a 123-bp fragment of the \textit{IS}6110 gene which is common among the members of the MTBC.

Real-time PCR and high-resolution melting analysis

Three pairs of primers (S1 Table) targeting specific sites at which mutations associated with RIF and INH drug resistance were utilized. One of each of the primer pairs, amplifying either the \textit{rpoB} [the 81-bp RIF resistance determining region (RRDR)], \textit{katG} [the -315 site (INH resistance)] and the promoter region of \textit{InhA} [the -8 and -15 sites (INH resistance)]. The amplification was carried out in a \textit{Bio-Rad CFX96 Touch}™ using a Lunar® Universal genotyping master mix. All qPCR assays were performed in a final volume of 20 \textit{$\mu$l reaction} mixture containing the following components per reaction: 1.25 \textit{$\mu$l (0.5 mM final concentration)} of each primer, 12.5 \textit{$\mu$l of 2X HRM PCR master mix}, 2 \textit{$\mu$l of PCR water} and 3 \textit{$\mu$l (5–50 ng) of genomic DNA}. The \textit{Bio-Rad CFX96 Touch}™ \textit{Real-Time PCR Detection System} was programmed for PCR amplification and a melting curve stage. The thermal cycling parameters were 10 min at 95°C of pre-PCR stage and an amplification stage of 40 cycles consisting of 95°C for 5 secs and 10 secs at 60°C. The qPCR amplification was followed by melt curve analysis, which was initiated by a holding step at 65°C for 5 sec (to allow reassociation of DNA), followed by a slow temperature increase to 95°C at a rate of 0.1°C/s with continuous fluorescence data acquisition. The wild-type MTB (H37Rv), and nuclease-free water were included in each run as positive control and negative controls respectively. The HRMA curve was analysed using \textit{Bio-Rad CFX96 Touch}™ manager software. Converting the wild-type melting profile to a horizontal line and normalizing the melting profiles of the analyzed samples against the wild-type profile provided the difference temperature plots (S1 Fig).
Statistical analysis
Data were entered into Microsoft Excel 2010 software and then exported to SPSS version 25 (IBM, Chicago, USA) for analysis. The Chi-square test was computed to determine significance for observed differences. The threshold for statistical significance was set at $p \leq 0.05$.

Results
A total of 283 sputum samples were analyzed, out of which 266 were from newly diagnosed patients and 17 previously treated patients. The median age of all patients was 36 years and the majority were male TB patients (73.1%). 5.7% and 6.4% of the samples were collected from prisoners and refugees respectively (Table 1).

The overall monoresistance to rifampicin and isoniazid was found in 11% (95% CI: 0.077–0.150; $p$, 0.087) and 8.5% (95% CI: 0.056–0.123; $p$, 0.692) of the patients, respectively. Monoresistance to rifampicin and isoniazid was found in 11% (95% CI: 0.077–0.150; $p$, 0.087) and 8.5% (95% CI: 0.056–0.123; $p$, 0.692) of all the patients, respectively. Resistance to RIF and INH among newly diagnosed patients was 10.2% and 8.6%, while among previously treated patients, resistance to RIF and INH was 23.5% and 5.9% respectively. Furthermore, 4.9% of the samples from newly diagnosed with INH monoresistance, were found to have mutations in the InhA region while 8.6% had mutations in the katG region, a condition that can lead to phenotypic isoniazid drug resistance [2]. The overall resistance to both drugs (MDR-TB) was 6.7% (95% CI: 0.026–0.075; $p$, 0.982) among all patients (6.4% among newly diagnosed and 11.8% among previously treated patients). Of the cases with MDR-TB, 6.4% had mutations in both the rpoB and KatG regions, while 3.9% had mutations in both the rpoB and InhA sites (Table 2).

Bivariate analysis revealed that the previously treated patients were more likely to have MDR than the newly diagnosed patients (cOR: 1.092; 95% CI: 0.137–8.737). This relation, however, was not statistically significant ($p > 0.05$) given the very low sample size of the previously treated patients sample. Furthermore, there was a substantial correlation between age

| Characteristic | Category | $N = 283; n (%)$ |
|---------------|----------|-----------------|
| Age           | $\leq 24$ | 45 (15.9)       |
|               | 25–44    | 158 (55.8)      |
|               | 45–64    | 57 (20.1)       |
|               | $\geq 65$ | 23 (8.1)        |
| Gender        | Male     | 207 (73.1)      |
|               | Female   | 76 (26.9)       |
| HIV Status    | Positive | 76 (26.9)       |
|               | Negative | 78 (27.6)       |
|               | Unknown  | 129 (45.6)      |
| Level of income | High   | 23 (8.1)        |
|               | Low      | 260 (91.9)      |
| Prisoner      | No       | 267(94.3)       |
|               | Yes      | 16 (5.7)        |
| Refugee       | No       | 246 (86.9)      |
|               | Yes      | 37 (13.1)       |
| TB in the past | No      | 266 (94)        |
|               | Yes      | 17 (6)          |

https://doi.org/10.1371/journal.pone.0259221.t001
and drug resistance: patients aged 25 to 44 years old (COR 0.253; 95% CI: 0.070–0.922; p = 0.037) were more likely to have MDR-TB. Among all the patients included in this study, 54.4% of them had their HIV status known at the time of the study, with 26.9% of them being HIV positive. There was no substantial correlation between MDR-TB HIV infection and this category of patients (p = 0.324). No other variables were observed to be associated with MDR-TB in the region (Table 3).

**Discussion**

This study sought to determine the prevalence of RIF and INH resistance among PTB patients in Southwestern Uganda. DNA obtained from 283 sputum samples (each from an individual patient) were analysed. The overall prevalence of RIF and INH monoresistance was found to be at 11% and 8.5% respectively. This was significantly higher than that of a similar study carried out in part of this region between May 2007 and April 2008 which found RIF and INH monoresistance rates were at 4.8 and 3.2 per cent, respectively [23]. Studies have shown that an increase in drug resistance levels can be attributed to a variety of factors, including delayed diagnosis, non-continuous drug resistance surveillance [24, 25], and TB medication stock-outs in health facilities [19] resulting in treatment interruptions and the spread of drug-resistant strains in the population. Furthermore, studies have also shown that health care workers especially those involved in tuberculosis infection control, diagnosis, and treatment are a risk factor for resistance to any anti-TB medication [25]. However, studies are needed to investigate the role of such factors, and any other ones, in the rise of drug resistance in this region.

Our findings show that RIF monoresistance was higher (23.5%) in those patients with a history of prior TB treatment as compared to 10.2% of those newly diagnosed patients, while the rate of MDR was 6.4% and 11.8% in newly diagnosed and previously treated patients, respectively. Studies have shown that previous TB drug exposure, especially in inadequate or inappropriate doses, can result in an increased risk of developing mono-drug or multidrug-resistant tuberculosis [25–28]. The findings of this study of higher prevalence of MTB drug resistance among previously treated patients is consistent with findings of other Ugandan studies [25, 29, 30] and other neighbouring countries [4, 31, 32]. These high levels of drug resistance among previously treated patients raise concerns about TB treatment compliance and the successful application of drug resistance preventive measures such as directly observed
therapy (DOT) [9, 19]. More research, however, is needed to better understand the underlying causes of this greater occurrence of drug resistance among this category of patients in this region. There is also a need to reinforce and ensure strict compliance with the various policies developed by the Ministry of Health and the National Tuberculosis and Leprosy Program (NTLP).

Our study showed no significant association between patient characteristics such as imprisonment, refugee status, or HIV status and the development of MDR-TB, despite some studies showing that such factors are a strong independent risk factor for MDR-TB [4, 27, 33, 34]. For example, TB patients co-infected with HIV [35, 36] and the refugees [37, 38] are more likely to develop MDR-TB. Nevertheless, our results are comparable to those of a national survey of drug-resistant TB in Uganda [25] and a recent study in Arua [24], which found no significant association between HIV-TB co-infection and the development of MDR-TB. Nonetheless, integrated HIV/TB management is important for both diseases’ management. Disaggregated by age, our study showed that the patients aged 25 to 44 years had higher levels of MDR-TB (cOR 0.253; 95% CI: 0.070–0.922), suggesting that this category of patients are at a higher risk of having MDR-TB than the older population.

Table 3. Bivariate analysis of factors associated with multidrug resistance among PTB patients in southwestern Uganda.

| Risk factor         | RIF/INH Susceptible, n (%) | RIF/INH resistant, n (%) | cOR (95% CI) | P-value |
|---------------------|----------------------------|--------------------------|--------------|---------|
| Age (years)         |                            |                          |              |         |
| ≤ 24                | 43 (95.6)                  | 2 (4.4)                  | 0.221 (0.037–1.312) | 0.097   |
| 25–44               | 150 (94.9)                 | 8 (5.1)                  | 0.253 (0.070–0.922) | 0.037*  |
| 45–64               | 53 (93.0)                  | 4 (7.0)                  | 0.358 (0.081–1.577) | 0.175   |
| ≥ 65                | 19 (82.6)                  | 4 (17.4)                 | 1.000        | -       |
| Gender              |                            |                          |              |         |
| Male                | 193 (93.2)                 | 14 (6.8)                 | 1.306 (0.416–4.098) | 0.648   |
| Female              | 72 (94.7)                  | 4 (5.3)                  | 1.000        | -       |
| Level of income     |                            |                          |              |         |
| low                 | 244 (93.8)                 | 16 (6.2)                 | 0.689 (0.148–3.199) | 0.634   |
| High                | 21 (91.3)                  | 2 (8.7)                  | 1.000        | -       |
| HIV status          |                            |                          |              |         |
| Positive            | 72 (94.7)                  | 4 (5.3)                  | 0.968 (0.274–3.422) | 0.960   |
| Negative            | 71 (91.0)                  | 7 (9.0)                  | 1.718 (0.579–5.099) | 0.329   |
| Unknown             | 122(94.6)                  | 7 (5.4)                  | 1.000        |         |
| TB in the past      |                            |                          |              |         |
| No                  | 249 (93.6)                 | 17 (6.4)                 | 1.092 (0.137–8.737) | 0.934   |
| Yes                 | 16 (94.1)                  | 2 (11.8)                 | 1.000        | -       |
| Refugee             |                            |                          |              |         |
| No                  | 229 (93.1)                 | 17 (6.9)                 | 2.672 (0.345–20.701) | 0.347   |
| Yes                 | 36 (97.3)                  | 1 (2.7)                  | -            | -       |
| Prisoner            |                            |                          |              |         |
| No                  | 249 (93.3)                 | 18 (6.7)                 | -            | -       |
| Yes                 | 16 (100.0)                 | 0                        | -            | -       |

Variables included in the bivariate model: age, gender, HIV status, level of income, imprisonment, refugee status and previous history of TB;

*Statistically significant at 95% level of confidence;
cOR: adjusted odds ratio.

https://doi.org/10.1371/journal.pone.0259221.t003
Study limitations
We did not test for all the possible mutations associated with rifampicin and isoniazid resistance. However, we targeted the most dominant mutations associated with rifampicin and isoniazid resistance, hence likely that we identified a majority of the resistance to these drugs in the region. Another significant limitation of our analysis is the small sample size of the patients who have previously been treated for tuberculosis, which limits the precision with which we can estimate the relationship between prior treatment experience and the likelihood of developing drug resistance. Furthermore, HIV testing was not conducted on patients who did not know their HIV status at the time of the study, which could not enable us to conclude on HIV as a risk factor for drug resistance.

Conclusion
There is a relatively high prevalence of MDR-TB among PTB patients in Southwestern Uganda since settings with an MDR-TB prevalence of more than 3% especially among newly treated patients are considered as having a high MDR-TB burden (WHO 2015). This highlights the value of continuous drug resistance screening for all TB patients, as well as the strengthening of drug resistance control measures.

Supporting information
S1 Table. Primer pairs utilized in the high-resolution melting temperature curve analysis. (TIF)
S1 Fig. An illustration of the RT-PCR (Bio-Rad CFX96 Touch™) high-resolution melting temperature curve analysis using rpoB primers. a) melt temperature of the target region b) derived melting curve. Green = sample; Black = negative control and Red = Positive control. (TIF)

Acknowledgments
We gratefully acknowledge the technical help provided by the TB laboratory staff of Kabale and Mbarara regional referral hospitals, Nakivale health centre, and the Genomics and Translational laboratory of Mbarara University of Science and Technology.

Author Contributions
Conceptualization: Lisa Nkatha Micheni, Joel Bazira.
Data curation: Lisa Nkatha Micheni, Kennedy Kassaza, Ibrahim Ntulume.
Formal analysis: Lisa Nkatha Micheni, Kennedy Kassaza, Hellen Kinyi, Ibrahim Ntulume.
Funding acquisition: Lisa Nkatha Micheni.
Investigation: Lisa Nkatha Micheni, Joel Bazira.
Methodology: Lisa Nkatha Micheni, Kennedy Kassaza, Joel Bazira.
Project administration: Joel Bazira.
Resources: Lisa Nkatha Micheni, Joel Bazira.
Supervision: Joel Bazira.
Visualization: Lisa Nkatha Micheni.
Writing – original draft: Lisa Nkatha Micheni.
Writing – review & editing: Lisa Nkatha Micheni, Kennedy Kassaza, Hellen Kinyi, Ibrahim Ntulume, Joel Bazira.

References

1. Streicher E. M. et al., “Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa,” Infect. Genet. Evol., vol. 12, no. 4, pp. 686–694, 2012, https://doi.org/10.1016/j.meegid.2011.07.019 PMID: 21839855
2. Palomino J. C., “Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis,” FEMS Immuno Med Microbiol, vol. 56, no. 2, pp. 1–9, 2009, https://doi.org/10.1111/j.1574-696X.2009.00555.x PMID: 19416361
3. Gygli S. M., Borrell S., Trauner A., and Gagneux S., “Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives,” FEMS Microbiol. Rev., vol. 41, pp. 354–373, 2017, https://doi.org/10.1093/femsrev/fux011 PMID: 28369307
4. Kidunya B. R. et al., “Epidemiology and genetic diversity of multidrug-resistant tuberculosis in East Africa,” Tuberculosis, vol. 94, no. 1, pp. 1–7, 2014, https://doi.org/10.1016/j.tube.2013.08.009 PMID: 24215798
5. Zetola N. M. et al., “Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests,” J. Infect. Dis., vol. 209, no. 11, pp. 1754–1763, 2014, https://doi.org/10.1093/infdis/jiu040 PMID: 24443546
6. Nachega J. B. and Chaisson R. E., “Tuberculosis drug resistance: A global threat,” Clin. Infect. Dis., vol. 36, no. SUPPL. 1, 2003, https://doi.org/10.1086/344657 PMID: 12516027
7. WHO, Global Tuberculosis report 2018, 2018th ed. Geneva: World Health Organization, 2018.
8. Kola Oyediran et al., “Quality of Tuberculosis Services Assessment in Uganda,” 2020. [Online]. https://www.measureevaluation.org/resources/tr-20-398.html.
9. Iseman M. D., “Tuberculosis therapy: Past, present and future,” Eur. Respir. Journal, Suppl., vol. 20, no. 36, pp. 87–94, 2002, https://doi.org/10.1183/09031936.02.0309102 PMID: 12168751
10. Ramirez M. V. et al., “Rapid detection of multidrug-resistant Mycobacterium tuberculosis by use of real-time PCR and high-resolution melt analysis,” J. Clin. Microbiol., vol. 48, no. 11, pp. 4003–4009, 2010, https://doi.org/10.1128/JCM.00812-10 PMID: 20810777
11. Khosravi A. D., Goodarzi H., and Alavi S. M., “Detection of genomic mutations in katG, inhA and rpoB genes of Mycobacterium tuberculosis isolates using polymerase chain reaction and multiplex allel-specific polymerase chain reaction,” Brazilian J. Infect. Dis., vol. 16, no. 1, pp. 57–62, 2012, https://doi.org/10.1016/s1413-8670(12)70275-1 PMID: 22958357
12. Anthwal D., Gupta R. K., Bhalla M., Bhatnagar S., Tyagi J. S., and Haldar Sagarika, “Direct Detection of Rifampin and Isoniazid Resistance in Sputum Samples from Tuberculosis Patients by High-Resolution Melt Curve Analysis,” J. Clin. Microbiol., vol. 55, no. 6, pp. 1755–1766, 2017. https://doi.org/10.1128/JCM.02104-16 PMID: 28330890
13. Bwanga F., Joloba M. L., Haile M., and Hoffner S., “Evaluation of seven tests for the rapid detection of multidrug-resistant tuberculosis in Uganda,” Int. J. Tuberc. Lung Dis., vol. 14, no. 7, pp. 890–895, 2010. PMID: 20550770
14. Chen X., Kong F., Wang Q., Li C., Zhang J., and Gilbert G. L., “Rapid detection of isoniazid, rifampin, and ofloxacin resistance in mycobacterium tuberculosis clinical isolates using high-resolution melting analysis,” J. Clin. Microbiol., vol. 49, no. 10, pp. 3450–3457, 2011, https://doi.org/10.1128/JCM.01068-11 PMID: 21832014
15. Araujo S. et al., “qPCR-High resolution melt analysis for drug susceptibility testing of Mycobacterium leprae directly from clinical specimens of leprosy patients,” PLoS Negl. Trop. Dis., vol. 11, no. 6, pp. 1–18, 2017, https://doi.org/10.1371/journal.pntd.0005506 PMID: 28570560
16. Galarza M. et al., “High-resolution melting analysis for molecular detection of multidrug resistance tuberculosis in Peruvian isolates,” BMC Infect. Dis., vol. 16, no. 1, pp. 1–6, 2016, https://doi.org/10.1186/s12879-016-1615-y PMID: 27278526
17. Arefzadeh S. et al., “High-resolution melt curve analysis for rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a single-centre study in Iran,” New Microbes New Infect., vol. 35, p. 100665, 2020, https://doi.org/10.1016/j.nmni.2020.100665 PMID: 32257224
18. Ministry of Health, “Annual Health Sector Performance Report FY 2019/20,” 2020. [Online]. http://library.health.go.ug/publications/performance-management/annual-health-sector-performance-report-financial-year-201920.
19. Elizabeth Glaser Foundation, “Strengthening the Tuberculosis and HIV / AIDS Response in the South-West Region of Uganda (STAR-SW) Project,” 2015.
20. Cochran W. G., *Sampling Techniques*, 2nd edn., vol. 2. New York: John Wiley and Sons, 1963.
21. Miljković-Selimović B., Kocić B., Babić T., and Ristić L., “Bacterial typing methods,” *Acta Fac. Medicae Naissensis*, vol. 26, no. 4, pp. 225–233, 2009.
22. CLSI, *Laboratory detection and identification of mycobacteria: approved standard*, M48-A ed., vol. 28, no. 17. Pennsylvania: Clinical and Laboratory Standards Institute, 2008.
23. Bazira J., Asimwe B. B., Joloba M. L., Bwanga F., and Matee M. I., “Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in South-Western Uganda,” *BMC Infectious Diseases*, vol. 11, no. 1. p. 81, 2011, https://doi.org/10.1186/1471-2334-11-81 PMID: 21453482
24. Okethwangi D. et al., “Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017,” *BMC Infect. Dis.*, vol. 19, no. 1. pp. 1–10, 2019. https://doi.org/10.1186/s12879-018-3567-x PMID: 30606108
25. Lukoye D. et al., “Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results of the First National Survey,” *PLoS One*, vol. 8, no. 8. 2013, https://doi.org/10.1371/journal.pone.0070763 PMID: 23936467
26. R. C. G. and B. G. P., Zetola Nicola M., Modongo Chawangwa, Moonan Patrick K., Ncube Ronald, et al, “Clinical Outcomes Among Persons With Pulmonary Tuberculosis Caused by Mycobacterium tuberculosis Isolates With Phenotypic Heterogeneity in Results of Drug-Susceptibility Tests,” *J. Infect. Dis.*, vol. 11, no. 1. pp. 1754–1763, 2014.
27. Faustini A., Hall A. J., and Perucci C. A., “Risk factors for multidrug resistant tuberculosis in Europe: A systematic review,” *Thorax*, vol. 61, no. 2. pp. 158–163, 2006, https://doi.org/10.1136/thx.2005.045963 PMID: 16250456
28. Zhao Y. et al., “National survey of drug-resistant tuberculosis in China,” *N. Engl. J. Med.*, vol. 366, no. 23, pp. 2161–2170, 2012, https://doi.org/10.1056/NEJMoai1108789 PMID: 22670902
29. Baluku J. B., Mugabe P., Mulwana R., Nassozi S., Katuramu R., and Worodria W., “High Prevalence of Rifampicin Resistance Associated with Rural Residence and Very Low Bacillary Load among TB/HIV-coinfected Patients at the National Tuberculosis Treatment Center in Uganda,” *Biomed Res. Int.*, vol. 2020, 2020. https://doi.org/10.1155/2020/2508283 PMID: 32775411
30. Kigozi E. et al., “Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda,” *PLoS One*, vol. 13, no. 5. pp. 1–17, 2018, https://doi.org/10.1371/journal.pone.0198091 PMID: 29847567
31. Wangui P., Kariuki S., Ng Z., and Revathi G., “Resist ance patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Nairobi,” *Public Health*, 2009.
32. Range N. et al., “Anti-tuberculosis drug resistance pattern among pulmonary tuberculosis patients with or without HIV infection in Mwanza, Tanzania,” *Tanzan. J. Health Res.*, vol. 14, no. 4. pp. 1–9, 2012, https://doi.org/10.4314/thbr.v14i4.2
33. Cohen T. et al., “Within-host heterogeneity of mycobacterium tuberculosis infection is associated with poor early treatment response: A prospective cohort study,” *J. Infect. Dis.*, vol. 213, no. 11. pp. 1796–1799, 2016, https://doi.org/10.1093/infdis/jiw014 PMID: 26768249
34. Suchindran S., Brouwer E. S., and Van Rie A., “Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review,” *PLoS One*, vol. 4, no. 5. 2009, https://doi.org/10.1371/journal.pone.0005561 PMID: 19440304
35. Harries A. D. et al., “The HIV-associated tuberculosis epidemic-when will we act?,” *Lancet*, vol. 375, no. 9729, pp. 1906–1919, 2010, https://doi.org/10.1016/S0140-6736(10)60409-6 PMID: 20488516
36. Shin S. S., Modongo C., Ncube R., Sepako E., Klausner J. D., and Zetola N. M., “Advanced immune suppression is associated with increased prevalence of mixed-strain mycobacterium tuberculosis infections among persons at high risk for drug-resistant tuberculosis in Botswana,” *J. Infect. Dis.*, vol. 211, no. 3. pp. 347–351, 2015, https://doi.org/10.1093/infdis/jiu421 PMID: 25070941
37. Chihota V. N. et al., “Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa,” *J. Clin. Microbiol.*, vol. 50, no. 3. pp. 995–1002, 2012, https://doi.org/10.1128/JCM.05832-11 PMID: 22170931
38. Mattei A. et al., “Cameroon’s multidrugresistant tuberculosis treatment programme jeopardised by crossborder migration,” *Eur. Respir. J.*, vol. 47, no. 2. pp. 686–688, 2016, https://doi.org/10.1183/13993003.01597-2015 PMID: 26828059